医学
2019年冠状病毒病(COVID-19)
淋巴细胞
炎症
中性粒细胞与淋巴细胞比率
全身炎症
单核细胞
流行病学
免疫学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
内科学
重症监护医学
疾病
传染病(医学专业)
作者
Jakub Wiktor Kosidło,Blanka Wolszczak-Biedrzycka,Joanna Matowicka-Karna,Violetta Dymicka-Piekarska,Justyna Zińczuk
摘要
Nowadays, society is increasingly struggling with infectious diseases that are characterized by severe course and even death. Recently, the whole world has faced the greatest epidemiological threat, which is COVID-19 caused by SARS CoV-2 virus. SARS CoV-2 infection is often accompanied by severe inflammation, which can lead to the development of different complications. Consequently, clinicians need easily interpreted and effective markers of inflammation that can predict the efficacy of the treatment and patient prognosis. Inflammation is associated with changes in many biochemical and hematological parameters, including leukocyte counts and their populations. In COVID-19, changes in leukocytes count populations such as neutrophils, lymphocytes or monocytes are observed. The numerous research confirm that indicators like neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelets-to-lymphocyte ratio (PLR) and systemic inflammatory index (SII) may prove effective in assessment patient prognosis and choosing optimal therapy. Therefore, in this review, we would like to summarize the latest knowledge about the diagnostic utility of systemic inflammatory ratios - NLR, LMR, PLR and SII in patients with COVID-19. We focused on the papers evaluating the diagnostic utility of inflammatory ratios using ROC curve published in the recent 3 years. Identification of biomarkers associated with inflammation would help the selection of patients with severe course of COVID-19 and high risk of death.
科研通智能强力驱动
Strongly Powered by AbleSci AI